Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year. Alvotech signed new commercialization agreements for its high concentration interchangeable biosimilar to Humira® in the U.S. and for its proposed biosimilar to Prolia® and Xgeva® in the U.S. and Europe. Alvotech raises topline revenue guidance to $400-$500 million and tightens guidance for bottom line ...

Financial Performance - Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year [1] - Gross margin in Q1 2024 increased to $17 million, up by $40 million compared to the same period last year [1] - Product revenue was $12.4 million for the three months ended March 31, 2024, compared to $15.7 million for the same period in 2023 [8] - License and other revenue was $24.4 million for the three months ended March 31, 2024, with no license and other revenue recognized in the same period of 2023 [9] - Reported net loss was $218.7 million, or ($0.89) per share for Q1 2024, compared to a net loss of $276.2 million, or ($1.24) per share for the same period in 2023 [14] Business Developments - Alvotech signed new commercialization agreements for its high concentration interchangeable biosimilar to Humira® in the U.S. and for its proposed biosimilar to Prolia® and Xgeva® in the U.S. and Europe [1] - The FDA approved AVT04, a biosimilar to Stelara®, for marketing in the U.S. under the tradename Selarsdi, with launches planned in Canada, Japan, Europe, and the U.S. [5] - Alvotech announced a strategic partnership with Quallent Pharmaceuticals for the distribution of its high-concentration interchangeable biosimilar to Humira [5] - A commercial partnership agreement was signed with Dr. Reddy's Laboratories for the commercialization of AVT03, a biosimilar candidate to Prolia® and Xgeva® [6] Guidance and Future Outlook - Alvotech raised topline revenue guidance for 2024 to $400-$500 million and tightened guidance for EBITDA to $100-$150 million for the full year [1][4] - Management will conduct a business update conference call on May 22, 2024, to discuss further developments [1][15]

Core Insights - Dr. Reddy's Laboratories has secured exclusive commercialization rights for AVT03, a biosimilar candidate to Prolia® and Xgeva®, in the U.S. and semi-exclusive rights in Europe and the UK [1][2] - Alvotech will handle the development and manufacturing of AVT03, while Dr. Reddy's will manage registration and commercialization in the relevant markets [2][3] - The agreement includes an upfront payment to Alvotech, with additional payments tied to regulatory and commercialization milestones, as well as sales-based payments [2] Company Overview - Dr. Reddy's Laboratories is a global pharmaceutical company based in Hyderabad, India, focusing on providing affordable and innovative medicines across various therapeutic areas [7][8] - The company has developed a portfolio of biosimilar products and aims to expand its offerings in highly regulated markets [3][8] - Alvotech is a biotech company dedicated to developing and manufacturing biosimilar medicines, with a current pipeline of eight biosimilar candidates targeting various diseases [12] Product Information - AVT03 is a human monoclonal antibody biosimilar candidate to denosumab, indicated for treating osteoporosis and preventing skeletal-related events in patients with advanced malignancies [4] - Positive top-line results from a pharmacokinetic study of AVT03 compared to Prolia® were announced in January 2024, with ongoing studies to confirm efficacy and safety [4] Strategic Collaboration - The partnership between Dr. Reddy's and Alvotech aims to enhance the availability of cost-effective biologic medications globally, emphasizing the importance of biosimilars in healthcare systems [3][12] - Both companies share a commitment to improving patient access to safe and effective biologics, leveraging their combined resources for better service delivery [3][12]

Dr. Reddy's gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the product HYDERABAD, India and REYKJAVIK, Iceland, May 21, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ("Alvotech"), and Dr. Reddy's Laboratories SA, wholly-owned subsidiary ...

Core Viewpoint - Teva Pharmaceuticals and Alvotech have launched SIMLANDI, the first interchangeable high-concentration, citrate-free biosimilar to Humira in the U.S. for various autoimmune conditions, aiming to provide cost-effective treatment options and improve patient access [1][2][3] Company Overview - Teva Pharmaceutical Industries Ltd. is a global leader in pharmaceuticals with a focus on generics and innovation, employing 37,000 people across 58 markets [5] - Alvotech specializes in the development and manufacture of biosimilar medicines, aiming to be a global leader in the biosimilar space with a pipeline of eight disclosed candidates [6][7] Product Details - SIMLANDI (adalimumab-ryvk) is approved by the FDA for multiple indications including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis [1][8] - The product is notable for being the first high-concentration, citrate-free biosimilar to Humira with interchangeability exclusivity for the 40mg/0.4mL injection, addressing the majority of U.S. prescriptions for adalimumab, which are for high-concentration presentations [2][3] Strategic Partnership - Teva and Alvotech formed a strategic partnership in August 2020 for the exclusive commercialization of Alvotech's biosimilar candidates, which has since expanded to include additional products [3] - The partnership allows Alvotech to focus on development and manufacturing while Teva leverages its extensive sales and marketing infrastructure for commercialization in the U.S. [3] Market Impact - The launch of SIMLANDI is expected to create cost-saving opportunities across the healthcare system, contributing to reduced inflationary pressure for healthcare providers and patients [2][3] - Teva is committed to bringing six additional biosimilars to market by 2027, indicating a strong pipeline and focus on expanding its biosimilar offerings [2]

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ  — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosin ...

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult p ...

REYKJAVIK, Iceland, May 13, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2024, after U.S. markets close on Tuesday, May 21, 2024. Alvotech will also conduct a conference call with analysts to present the first quarter 2024 financial results and recent business highlights on Wednesday May 22, 20 ...

REYKJAVIK, Iceland, May 02, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of management would be participating in the upcoming BofA Securities Healthcare Conference 2024, which will be held on May 14-15, 2024 in Las Vegas, NV. Members of Alvotech's management team will be attending the conference and hosting one-on-one meetings with investors. About Alvotec ...

The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritisAlvotech is the first company to publicly announce positive topline results from a patient study evaluating a biosimilar candidate to Simponi or Simponi Aria REYKJAVIK, Iceland, April 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufa ...